These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36948504)

  • 1. Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).
    Atkins MB; Jegede OA; Haas NB; McDermott DF; Bilen MA; Stein M; Sosman JA; Alter R; Plimack ER; Ornstein MC; Hurwitz M; Peace DJ; Signoretti S; Denize T; Cimadamore A; Wu CJ; Braun D; Einstein D; Catalano PJ; Hammers H
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36948504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).
    Atkins MB; Jegede OA; Haas NB; McDermott DF; Bilen MA; Stein M; Sosman JA; Alter R; Plimack ER; Ornstein M; Hurwitz M; Peace DJ; Signoretti S; Denize T; Cimadamore A; Wu CJ; Braun D; Einstein D; Catalano PJ; Hammers H
    J Clin Oncol; 2022 Sep; 40(25):2913-2923. PubMed ID: 35442713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
    Atkins MB; Jegede OA; Haas NB; Mcdermott DF; Bilen MA; Stein M; Sosman J; Alter R; Plimack ER; Ornstein MC; Hurwitz M; Peace DJ; Einstein D; Catalano PJ; Hammers H; Regan MM
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
    Tykodi SS; Gordan LN; Alter RS; Arrowsmith E; Harrison MR; Percent I; Singal R; Van Veldhuizen P; George DJ; Hutson T; Zhang J; Zoco J; Johansen JL; Rezazadeh Kalebasty A
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study.
    Izumi K; Inoue M; Washino S; Shirotake S; Kagawa M; Takeshita H; Miura Y; Hyodo Y; Oyama M; Kawakami S; Miyagawa T; Saito K; Kageyama Y
    Int J Urol; 2023 Sep; 30(9):714-721. PubMed ID: 36541136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma.
    Conduit C; Davis ID; Goh JC; Kichenadasse G; Gurney H; Harris CA; Pook D; Krieger L; Parnis F; Underhill C; Adams D; Roncolato F; Joshua A; Ferguson T; Prithviraj P; Morris M; Harrison M; Begbie S; Hovey E; George M; Liow EC; Link EK; McJannett M; Gedye C; ;
    BJU Int; 2024 Feb; 133 Suppl 3():57-67. PubMed ID: 37986556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis.
    Chahoud J; Msaouel P; Campbell MT; Bathala T; Xiao L; Gao J; Zurita AJ; Shah AY; Jonasch E; Sharma P; Tannir NM
    Oncologist; 2020 Mar; 25(3):252-258. PubMed ID: 32162795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage nivolumab and ipilimumab after prior anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma: A meta-analysis.
    Yang Y; Mori SV; Li M; Hinkley M; Parikh AB; Collier KA; Miah A; Yin M
    Cancer Med; 2022 Apr; 11(7):1669-1677. PubMed ID: 35138046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
    Vogelzang NJ; Olsen MR; McFarlane JJ; Arrowsmith E; Bauer TM; Jain RK; Somer B; Lam ET; Kochenderfer MD; Molina A; Doshi G; Lingerfelt B; Hauke RJ; Gunuganti V; Schnadig I; Van Veldhuizen P; Fleming M; Galamaga R; Gupta M; Hool H; Hutson T; Zhang J; McHenry MB; Johansen JL; Tykodi SS
    Clin Genitourin Cancer; 2020 Dec; 18(6):461-468.e3. PubMed ID: 32718906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
    Kim S; Wuthrick E; Blakaj D; Eroglu Z; Verschraegen C; Thapa R; Mills M; Dibs K; Liveringhouse C; Russell J; Caudell JJ; Tarhini A; Markowitz J; Kendra K; Wu R; Chen DT; Berglund A; Michael L; Aoki M; Wang MH; Hamaidi I; Cheng P; de la Iglesia J; Slebos RJ; Chung CH; Knepper TC; Moran-Segura CM; Nguyen JV; Perez BA; Rose T; Harrison L; Messina JL; Sondak VK; Tsai KY; Khushalani NI; Brohl AS
    Lancet; 2022 Sep; 400(10357):1008-1019. PubMed ID: 36108657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma.
    Gupta R; Ornstein MC; Li H; Allman KD; Wood LS; Gilligan T; Garcia JA; Merveldt DV; Hammers HJ; Rini BI
    Clin Genitourin Cancer; 2020 Dec; 18(6):429-435. PubMed ID: 32800717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma.
    Tachibana H; Kondo T; Ishihara H; Fukuda H; Yoshida K; Takagi T; Izuka J; Kobayashi H; Tanabe K
    Jpn J Clin Oncol; 2021 Apr; 51(4):646-653. PubMed ID: 33212488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.
    Choueiri TK; Kluger H; George S; Tykodi SS; Kuzel TM; Perets R; Nair S; Procopio G; Carducci MA; Castonguay V; Folefac E; Lee CH; Hotte SJ; Miller WH; Saggi SS; Lee CW; Desilva H; Bhagavatheeswaran P; Motzer RJ; Escudier B
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36328377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti-PD-1/PD-L1 Therapy.
    Carril-Ajuria L; Lora D; Carretero-González A; Martín-Soberón M; Rioja-Viera P; Castellano D; de Velasco G
    Clin Genitourin Cancer; 2021 Apr; 19(2):95-102. PubMed ID: 33189597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma.
    McKay RR; Leucht K; Xie W; Jegede O; Braun DA; Atkins MB; Grimm MO; Choueiri TK
    Oncologist; 2024 Apr; 29(4):324-331. PubMed ID: 37950901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
    D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H
    Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE).
    McKay RR; McGregor BA; Xie W; Braun DA; Wei X; Kyriakopoulos CE; Zakharia Y; Maughan BL; Rose TL; Stadler WM; McDermott DF; Harshman LC; Choueiri TK
    J Clin Oncol; 2020 Dec; 38(36):4240-4248. PubMed ID: 33108238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
    Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma.
    George G; Schmidt L; Tolat P; Riese M; Kilari D
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.
    Rini BI; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; George S; Powles T; Donskov F; Tykodi SS; Pal SK; Gupta S; Lee CW; Jiang R; Tannir NM
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36549781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.